Amgen Inc. has agreed to sell 30-year senior notes that will be converted into Amgen stock. Amgen expects to raise $2.8 billion from the offering.
Merrill Lynch & Co. Inc. was the underwriter.
Thousand Oaks' Amgen is a biotechnology company that produces drugs used to treat nephrology, cancer, inflammatory disorders and ne...
Merrill Lynch & Co. Inc. was the underwriter.
Thousand Oaks' Amgen is a biotechnology company that produces drugs used to treat nephrology, cancer, inflammatory disorders and ne...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In